Letrozol Almus Pharma (Letrozole)

Letrozole is an aromatase inhibitor employed in hormone‑dependent breast cancer management.

• Postmenopausal estrogen receptor‑positive breast cancer: reduces tumor growth by lowering estrogen levels.
• Adjuvant therapy for early‑stage breast cancer: decreases risk of disease recurrence after surgery.
• Metastatic breast cancer in postmenopausal women: helps control disease progression.

• Letrozole reversibly binds to the aromatase enzyme, inhibiting the conversion of androstenedione and testosterone into estrone and estradiol. By suppressing peripheral estrogen synthesis, it markedly lowers circulating estrogen concentrations, depriving estrogen‑dependent tumor cells of growth stimulation.

Letrozole may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Hot flashes: sudden feeling of warmth and sweating.
• Arthralgia: joint pain or stiffness.
• Fatigue: persistent tiredness.
• Nausea: mild stomach upset.
• Headache: occasional throbbing pain.
• Increased cholesterol: elevated lipid levels.

Serious or Rare Side Effects

• Osteoporosis: decreased bone mineral density leading to fractures.
• Deep vein thrombosis: blood clot formation in veins.
• Liver dysfunction: abnormal liver enzyme elevations.
• Severe allergic reaction: rash, swelling, or breathing difficulty.
• Cardiovascular events: heart attack or stroke.
• Vision changes: blurred vision or ocular discomfort.

Before using Letrozol Almus Pharma, consider the following precautions:

• Pregnancy: contraindicated; teratogenic risk (Category X).
• Breastfeeding: not recommended; drug may pass into milk.
• Bone health: monitor bone mineral density, supplement calcium/vitamin D as needed.
• Cardiovascular risk: assess history of heart disease before treatment.
• Liver function: perform baseline liver tests and monitor periodically.
• Drug interactions: review concomitant medications for potential interactions.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Letrozole can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP2A6 inducers (e.g., rifampin): may reduce letrozole plasma levels.
• Estrogen‑containing hormone therapy: antagonizes letrozole’s anti‑estrogen effect.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): may increase bleeding risk; monitor INR.
• Cholesterol‑lowering agents (e.g., statins): possible additive effect on liver enzymes.
• CYP2A6 inhibitors (e.g., fluvoxamine): may raise letrozole concentrations.
• SSRIs/SNRIs: may affect bone metabolism; monitor bone health.
• Herbal supplements (e.g., St. John’s wort): potential enzyme induction; advise caution.